A sensitive and specific diagnosis biomarker, in principle scalable to most cancer types, is needed to reduce the prevalent cancer mortality. Meanwhile, the investigation of diagnosis determinants of a biomarker will facilitate the interpretation of its screening results in clinic. Here we design a large-scale (1558 enrollments), multicenter (multiple hospitals), and cross-validation (two datasets) clinic study to validate plasma Hsp90α quantified by ELISA as a pan-cancer biomarker. ROC curve shows the optimum diagnostic cutoff is 69.19 ng/mL in discriminating various cancer patients from all controls (AUC 0.895, sensitivity 81.33% and specificity 81.65% in test cohort; AUC 0.893, sensitivity 81.72% and specificity 81.03% in validation cohort).
| INTRODUC TI ON
An accurate diagnosis biomarker, in principle for different types of cancer, is an alternative but economical way to prevent worldwide cancer deaths. Blood-based liquid biopsy represents a promising non-invasive clinical method for cancer detection. Increasing reports have focused on circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), serum noncoding RNAs, or exosomes as a way to identify tumor-associated biomarkers.
1 Emerging studies have attempted to integrate blood biomaterials to all-in-one biosources to detect patients with pan-cancer diseases. Initial studies have
shown that ctDNA was detectable in >75% patients with multiple advanced cancer diseases, but in <50% patients with local diseases.
2
A subsequent study suggested that RNA-seq of tumor-educated platelets achieved 96% accuracy for the detection of patients with multiclass cancers. 3 Papadopoulos's group developed a test called CancerSEEK, which combined the mutation of cell-free DNA and circulating proteins, and detected a median of 70% of eight cancer types. 4 However, limitations, including the absence of healthy controls or patients with at-risk diseases and no independent validation dataset, should be noted in stating these results. In addition, the involved technologies, referring to expensive high-throughput sequencing platforms and data analyses with support vector machines or other bioinformatics methods, often required highly experienced experts to operate the equipment and explain the data, which hampers its translation to the clinic. Until this time, early detection of patients with cancer is critical, and a clinical usable detection platform is urgently needed.
Heat shock protein 90alpha (Hsp90α), a well studied molecular chaperone involved in stress tolerance, has recently been found to localize outside various cancer cells. 5 Extracellular Hsp90α (eHsp90α)
can promote cell invasion 6 and epithelial-to-mesenchymal transition (EMT) processes 7 in multiple cancer cells. Clinical trials have demonstrated that plasma Hsp90α is a more accurate diagnostic biomarker compared with commonly used biomarkers carcinoembryonic antigen (CEA) and fragments of cytokeratin-19 (CYFRA21-1) in lung cancer, 8 or alpha-fetoprotein (AFP) in liver cancer, 9 respectively.
In the clinic, a quantitative ELISA kit for plasma Hsp90α has now been approved by the China Food and Drug Administration (CFDA)
to be used for patients with lung or liver cancers (see http://www. sfda.gov.cn). Ongoing clinical trials, including with patients with colorectal or breast cancer, also showed that plasma Hsp90α is a much more precise diagnostic biomarker (to be published). Together, this evidence provides a strong rational to generalize the quantitation of plasma Hsp90α based on ELISA in the diagnosis of patients with multiclass cancer. If confirmed, this approach will represent plasma Hsp90α as a novel pan-cancer diagnostic biomarker. Therefore, we designed a large-scale, multicenter, and cross-validation study to assess the diagnostic accuracy of plasma Hsp90α as a biomarker for pan-cancer diseases.
After a potential biomarker has been translated into the clinic, there is almost no research to investigate the diagnostic determinants of the new or already existing tumor biomarkers. 10, 11 This situation makes it impossible to address causes and anticipated risks of outlier samples identified in the clinic such as limited sensitivities or patients with cancer identified erroneously as healthy individuals. We propose that the diagnostic performance is often limited to a poor understanding of the biology of a biomarker. Taking plasma Hsp90α as an example, two aspects should be considered to explain its diagnostic capability as a biomarker in the clinic: first, is to confirm whether plasma Hsp90α is actually secreted in ELISA-negative patients. Regarding this point, we need to understand thoroughly the upstream regulator controlling its secretion into the blood; and the second is to investigate whether the recognition ability of the antibody in the ELISA kit will be compromised by the heterogeneity of secreted Hsp90α. This aspect will lead to false ELISA-negative patients. As a result, we have investigated systematically determinants that could affect the diagnosis performance of plasma Hsp90α.
| MATERIAL S AND ME THODS

| Study design and participants in diagnosis
We conducted a prospective and tentative diagnosis study (e-CAF:
an early, Convenience, Accuracy, and Fast, pan-cancer diagnosis biomarker for patients with cancer) using an ELISA kit to measure quantitatively plasma Hsp90α from patients with different types of cancer. All these studies conformed to the provisions of the Declaration of Helsinki. The study was approved by the Institutional Review Board of Tsinghua University, China.
| Participants enrolled in the test cohort
In the test cohort, 628 participants, consisting of 300 patients with 
| Data compiling in validation cohort
| Library preparation for RNA-seq
Total RNA was isolated from different subclonal populations using TRIzol reagent (Invitrogen). The quality of extracted RNA was determined using capillary electrophoresis on a Bioanalyzer 2100 instrument (Agilent Technologies). mRNA with a polyA tail was enriched using oligo(dT) magnetic beads, followed by DNase I (Invitrogen) incubation to remove genomic DNA. The target mRNA was fragmented and reverse transcribed into double-strand cDNA (dscDNA) using N6 random primers. After end repair with phosphate at the 5′ end and addition of "A" nucleotides at 3′ end, dscDNA was ligated with an adaptor containing "T" nucleotides at the 3′ end of the dscDNA. Next, ligation products were amplified with two specific primers; and the PCR product was denatured by heat, and the single-strand DNA cyclized (ssDNA circle) with a splint oligo and DNA ligase. Quality and quantity were confirmed by high sensitivity DNA assay on a Bioanalyzer 2100 instrument (Agilent Technologies). Library sequencing was then performed using a combinatorial probe-anchor synthesis (cPAS)-based BGISEQ-500 sequencer (BGI). Base calling was carried out with inhouse BGISEQ-500 software. 
|
| Reverse transcription and quantitative realtime PCR (qRT-PCR)
Total RNA was extracted from cell pellets using TRIzol reagent 
| Immunoprecipitation
Cells were lysed in ice-cold NP-40 lysis buffer (50 mmol/L Tris-HCl at pH 8.0, 150 mmol/L NaCl, 1% NP-40, protease inhibitors cocktail; Roche). Lysates were centrifuged for 10 min at 16 000 g at 4°C.
Supernatants were recovered and incubated with primary antibodies for more than 4 h at 4°C. Protein A/G agarose resin (Roche) was added to the mixture and tumbled in a tube rotator overnight at 4°C.
The immunoprecipitates bound to the resin were washed five times with lysis buffer, then re-suspended in sample loading buffer, and resolved by SDS-PAGE. 
| In vitro phosphorylation of rHsp90α by PKCγ
An in vitro PKCγ phosphorylation assay for rHsp90α was performed as described. 20 Briefly, recombinant Hsp90α and PKC were incu- 
| Immunofluorescence
For immunofluorescence to detect the colocalization of ADAM10
and Hsp90α, cells were seeded onto coated coverslips in 24-well plates overnight, fixed with 4% paraformaldehyde for 10 min at room temperature, and blocked with 10% goat serum for 60 min at room temperature, followed by incubation with indicated primary antibodies. Corresponding secondary antibodies labeled with different fluorochromes were used to visualize the target proteins. Images were acquired and analyzed using a Nikon A1 confocal microscope (Nikon).
| Immunohistochemistry (IHC)
Immunohistochemistry (IHC) was performed as described previously. 21 Briefly, to detect the expression of ADAM10 in a human cancer tissue microarray (MC2081a, Alenabio) and in animal tissue, tumor tissue slides were probed with primary antibodies at indicated concentrations overnight at 4°C, followed by incubation with HRP-conjugated secondary antibody at room temperature for 1 h.
Chromogenic 3,3′-diaminobenzidine (DAB) substrate was added to visualize the expression of the target proteins.
| Western blotting
Western blotting assays were performed as described in detail.
21
Cells were scraped off the culture plates, and washed twice with PBS. After centrifugation, cell pellets were collected, denatured with loading buffer, boiled for 15 min, and separated on 10% SDS-PAGE gels, followed by transfer to polyvinylidene difluoride (PVDF) membranes. The target proteins were probed with the indicated primary antibodies overnight at 4°C, then incubated with horseradish peroxidase (HRP)-conjugated secondary antibodies for 1 h at room temperature, and visualized using a common enhanced chemiluminescence technique (Beyotime) according to the manufacturer's protocol.
| Animal studies
All animal studies were approved by the Institutional Animal Care and Use Committee of Tsinghua University. Mice were housed in AAALA-approved laboratory animal care facilities. A549 and PANC1 cells (5 × 10 6 cells per mouse) stably knocking down ADAM10 mixed with Matrigel 1:1 were injected subcutaneously into 6-wk-old mice.
After 2 wk, mice were sacrificed and primary tumor tissues were embedded in paraffin, sectioned and applied for immunohistochemistry (IHC) analysis.
| Protein concentration determination
Protein concentrations were determined using the bicinchoninic acid ( BCA) protein assay (Pierce). 
| Quantitative proteomics for plasma
| Plasma sample preparation
Depletion of high abundance proteins, including immunoglobulin G (IgG) and albumin, from plasma samples was performed using
ProteoPrep Blue Albumin and IgG Depletion Kit (Sigma-Aldrich)
according to the manufacturer's instructions. Next, a 400 μL aliquot of suspended deletion medium was added to a spin column, and the column centrifuged at 8000 g for 5 s to remove the storage solution. Then depletion medium was equilibrated twice with 400 μL equilibration buffer. To discard the equilibration buffer, the spin column was centrifuged at 8000 g for 15-30 s. After the equilibration process, 25 μL of plasma sample was applied to the top of the packed medium and incubate at room temperature for 8 min, then the column was centrifuged at 10 000 g for 60 s. The elute in the collection tube was transferred to the top medium in the spin column, and incubated at room temperature for another 5 min, and centrifuged as before. The IgG/albumin-depleted plasma samples were stored at −20°C, until use.
| SDS-PAGE and trypsin digestion
Samples mixed with loading buffer were denatured at 95°C for 3 min, and separated on SDS-PAGE gels as previously described.
After electrophoresis, gels were stained for 1 h with Coomassie brilliant blue G-250 and destained overnight. Target bands were sliced from the gel, reduced with 10 mmol/L ammonium bicarbonate containing 10 mmol/L DTT, alkylated with 55 mmol/L iodoacetamide, treated with acetonitrile, and then the gel slice was digested with trypsin (Promega) in 50 mmol/L ammonium acetate containing 10% acetonitrile at 37°C overnight.
| Mass spectrometric analysis − parallel reaction monitoring
Parallel reaction monitoring (PRM) analysis was performed using a high-resolution Q Extractive hybrid mass spectrometer coupled with an UltiMate 3000 RSLCnano System (Thermo-Scientific). Briefly, peptides were injected into the UltiMate 3000 RSLCnano System through a reverse phase column silica C18 separate column (300 Å, 5 μm) using an acetonitrile gradient (0%-60% Buffer B in 80 min) at a flow rate of 200 nL/min into a high-resolution Q Extractive hybrid mass spectrometer. The buffer system was: Buffer A, 5% acetonitrile with 0.4% acetic acid and 0.005% heptafluorobutyric acid (HFBA), and Buffer B, 95% acetonitrile 0.4% acetic acid and 0.005% HFBA.
The mass spectrometer was operated in an automated data-dependent acquisition mode that was switched between MS scan and HCD-MS using Xcalibur 2.2.0 software. A single full-scan mass spectrum in Orbitrap (300-1800 m/z, 70 000 resolution) followed by 20 datadependent MS/MS scans at 27% normalized collision energy (HCD)
were collected.
| Quantitative analysis
The MS/MS spectra from each LC-MS/MS run were searched against human.fasta from UniProt using an in-house Proteome
Discoverer program (version PD1.4). The search criteria were as follows: full tryptic specificity was required; two missed cleavages were allowed; carbamidomethyl (C) was set as the fixed modifications; the oxidation (M) was set as the variable modification; precursor ion mass tolerances were set at 20 ppm for all MS acquired in the Orbitrap mass analyzer; and the fragment ion mass tolerance was set at 0.02 Da for all MS2 spectra acquired. 
| Exosomes isolation
Conditional medium was collected from cell cultures without serum. Exosomes were purified by sequential centrifugation steps.
Supernatant fractions were centrifuged at 300 g for 10 min, 20 000 g for 30 min, and then at 100 000 g for 70 min (Beckman). Exosomes pellets were washed again in PBS, and collected by ultracentrifugation at 100 000 g for 70 min.
| Electron microscopy
Exosomes were dropped onto a formvar-carbon-coated grid.
The grid was dried at room temperature for 8 min and viewed at ×20 000 and ×50 000 magnification using an electron microscope (Hitachi).
| Dynamic light scattering (DLS)
The mean hydrodynamic diameters of exosomes and size distribution were estimated by dynamic light scattering (DLS). The light scattering was recorded three times with 30 replicate measurements.
| Statistical analysis
| Statistical analysis in the diagnosis trial
Data were summarized as mean ± SD. Significance between two independent groups was tested using the non-parametric Wilcoxon MannWhitney U test. ROC curves were constructed to calculate sensitivity, specificity, and AUCs with 95% confidence interval (CI). The optimum cutoff values were determined according to the Youden index (J) method. 
| Statistical methods in biochemical research
Experiments were performed in triplicate, and results are shown as mean ± SD. Statistical tests between groups were determined using unpaired Student t test using SPSS software (Version 19.0). The chisquared test was used to test differences between categorical variables for tissue array. A P-value < .05 (two sided) was considered to be statistically significant. 
| RE SULTS
| Plasma Hsp90α is a novel pan-cancer diagnosis biomarker
To expand the diagnosis potential of plasma Hsp90α for multiple indications, 628 participants, including 300 patients with various cancer types, 196 with common at-risk diseases, and 132 healthy individuals, were prospectively recruited from hospitals into the test cohort ( Figure 1A and Supporting Information Figure S1 , Tables S1-S3). Plasma Hsp90α concentrations quantified by ELISA were significantly raised in patients with cancer (median 157.80 ng/mL, IQR 87.01-235.50 ng/mL; mean 180.30 ng/mL, SD 139.70) compared with those in the non-cancer control (P < .0001; Figure 1B and Table S4 ) and those in the at-risk control (P < .0001; Figure 1B and Table S4 ). The ROC curve determined the best cutoff value in cancer diagnosis as 69.19 ng/mL compared with the non-cancer control (AUC 0.895, 95% CI 0.870-0.919, sensitivity 81.33%, specificity 81.65%; Figure 1C and Table 1 ). Similar results were also noted when detecting patients with cancer from the at-risk control ( Figure 1C and Table 1 ).
To confirm the above results from the test cohort, we compiled the validation cohort from our curated clinical data corresponding to lung cancer, 8 breast cancer (to be published), colorectal cancer (to be published), and liver cancer 9 ( Figure S1 and Table S5 ). In the validation cohort, we found that plasma Hsp90α was at significantly different levels between patients with cancer and the non-cancer control (P < .0001; Figure 1D and Table S6 ). The ROC curve showed plasma Hsp90α had AUC 0.893 (95% CI 0.869-0.917, sensitivity 81.72% and specificity 81.03% under the optimum diagnostic cutoff 64.01 ng/mL) in discriminating patients with cancer from the noncancer control ( Figure 1E and Table 1 ). Similar results were found between patients with cancer and the at-risk group ( Figure 1E and Table 1 ). Plasma Hsp90α concentrations were also increased in patients with early-stage cancers compared with the non-cancer control ( Figure 1E and Table S6 ). In this setting, plasma Hsp90α
had an AUC 0.759 (0.697-0.820) with a sensitivity of 76.26% and specificity of 76.53% when using 56.38 ng/mL as the best cutoff value ( Figure 1E ad Figure 1F ). Collectively, these results proved that plasma Hsp90α is a novel pan-cancer diagnostic biomarker. 
| Plasma Hsp90α can also be a broad-spectrum biomarker for cancer subtypes
While α-fetoprotein (AFP) is a widely used serological biomarker, it could only be applicable for hepatocellular carcinoma (HCC).
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AFP-limited subtypes, including cholangiocarcinoma or combined hepatocellular carcinoma and cholangiocarcinoma, accounted for the second most common primary liver cancer patients. Due to a lack of a sensitive diagnosis biomarker, the overall survival of these patients was extremely poor. 25 Here we investigated the diagnostic capability of plasma Hsp90α as a broad-spectrum biomarker for cancer subtypes, with an emphasis on patients with liver cancer ( Figure S2 ). In this study, we found that plasma Hsp90α concentrations in AFP-limited liver cancer (median 182.90 ng/mL, IQR 120.60-272.40 ng/mL; mean 201.20 ng/mL; SD 107.40) were significantly elevated compared with the corresponding controls (P < .0001; Figure 2A and Table S7 ). The ROC curve was likewise used to evaluate the diagnosis performance of plasma Hsp90α in this setting. The results showed that the sensitivity of plasma Hsp90α to differentiate patients with AFP-limited liver cancer from the non-cancer control was 91.78% under the cutoff 66.44 ng/mL, and the specificity was 91.96% ( Figure 2B and Table S8 ). Similar results were also shown in comparison with other controls ( Figure 2B and Table S8 ). CA19-9 (37 U/mL), CA-125 (35-65 U/mL), CEA (5 ng/mL), and AFP (20 ng/mL) have been used as potential biomarkers for diagnosis of patients with AFP-limited liver cancer. 25 However, the positive ratio was only 37.86% for AFP, 18.27% for CEA, 37.50% for CA 19-9, and 19.42% for CA-125, in the diagnosis of AFP-limited liver cancer, respectively ( Figure 2C ).
In addition, we found that plasma Hsp90α had almost comparable diagnosis capability in different subtypes of other cancer types, including lung or colorectal cancer ( Figure 2D ). The above results demonstrated that plasma Hsp90α can also be a broad-spectrum biomarker among different cancer subtypes.
| Integrative analysis reveals that ADAM10 determines Hsp90α secretion in multiple cancer cell lines
Next, in the clinic, we investigated systematically the diagnosis determinants for plasma Hsp90α. The diagnostic performance was limited to actual situations by many factors. One of these was the upstream regulator involved in its secretion of the biomarker. To screen the factor(s) regulating the secretion of Hsp90α, we analyzed differential expression profiles between normal and tumor tissues from different types of cancer described in a public database (Table S9 ). Differentially expression genes were overlapped between different types of cancer ( Figure S3A ). Functional clustering analysis of altered genes revealed a significant enrichment of genes related to the regulation of cell development, response to growth factor, and tissue morphogenesis ( Figure S3B ). Focusing on the defined pathways regarding extracellular Hsp90α (eHsp90α) function, including extracellular matrix remodeling, 26 angiogenesis, 27 migration and invasion, 28, 29 and pathways mediating the secretion of exosomes, 30 genes were specifically chosen for further analysis ( Figure 3A) . It was hypothesized that, compared with cell lines that secreted low levels of Hsp90α, upregulated genes in high-secretion cell lines could contribute to its secretion. Therefore, the secretion of Hsp90α in different cell lines was first detected quantitatively ( Figure 3B ). Subsequently, a closer analysis of transcriptome levels between low-and high-secretion cell lines indicated that seven genes were correlated with the secretion of Hsp90α ( Figure S3C and Table S10 ). A small interfering RNA mini-screen identified ADAM10 as the most significant gene based on gene expression data and quantitative results of eHsp90α ( Figure 3C and Figure S3D ). ADAM10 knockdown consistently decreased the secretion of Hsp90α in other cancer cell lines ( Figure 3D ). Inhibition of ADAM10 by its inhibitor GI254023X also decreased the secretion of Hsp90α, but not proportionally to that in the knockdown experiment ( Figure S3E ). Transfection of a plasmid encoding a dominant-negative ADAM10 (ADAM10DN), which will compromise its sheddase function, 31 decreased slightly the secretion of eHsp90α ( Figure S3F ). To further confirm these findings in vivo, we detected quantitatively Hsp90α secretion in plasma from A375-shADAM10-derived and PANC1-shADAM10-derived xenografts ( Figure 3E,F) . Ex vivo quantitation revealed significantly decreased levels of plasma Hsp90α in comparison with that from wild-type mice ( Figure 3G ). These data determined that ADAM10 regulate the secretion of eHsp90α both in in vitro and in vivo models.
| ADAM10 is highly expressed in multiple cancers and correlated with levels of plasma Hsp90α
Previous reports have indicated that ADAM10 is overexpressed in several cancer types. 32, 33 In addition, levels of plasma Hsp90α were correlated with tumor malignancy in pan-cancer cases ( Figure 4A ).
Accordingly, we hypothesized that ADAM10 would be correlated with tumor malignancy in other major cancer types. To confirm this, we first examined protein levels of ADAM10 using immunohistochemistry in tissue microarray that contained five major epithelial carcinoma tissues, including breast, lung, prostate, colon, and rectum (Table S11) . Tissues were scored according to staining intensities of ADAM10 expression and the percentage area of cancer cells.
It was shown that expression of ADAM10 was significantly elevated in tissues from patients with cancer compared with those from normal controls ( Figure 4B,C) . Also, we found that the expression of ADAM10 in patients with late-stage diseases was significantly elevated compared with that in early-stage patients ( Figure 4C and Figure S4A ), which indicated that ADAM10 played a critical role in tumor progression.
To further establish in the clinic, the correlation between ADAM10 and the secretion of Hsp90α, we detected the expression of ADAM10 from patients with lung or colorectal cancer, in which | 2951
corresponding levels of plasma Hsp90α from the same patients were quantified by the ELISA kit. The results showed that high expression of ADAM10 was correlated with the levels of plasma Hsp90α in both cancer types ( Figure 4D-F) . The above results proved that ADAM10
was correlated with the secretion of Hsp90α in patients and will determine diagnostic performance of biomarker plasma Hsp90α. Data are represented as mean ± SD. *P < .05; **P < .01; ***P < .001 
| ADAM10 affects the content of Hsp90α in exosomes, not the classical direct sheddase function
The mechanism underlying ADAM10 that regulates the secretion of Hsp90α is unknown. ADAM10, a single-pass transmembrane protein with multiple organized modular domains ( Figure 5A ), is well known as the major sheddase in physiological process. 34 In the ADAM family of sheddase, several other proteolytic members closely related to ADAM10 were also overexpressed in human cancers ( Figure   S5A ). To confirm the findings that ADAM10, rather than other A Disintegration And Metalloproteinase domain-containing proteins (ADAMs), regulates the secretion of Hsp90α, we used an RNA Figure 5C ). The secretion of Hsp90α was reported to be through the exosome pathway. 30 Therefore, we detected the effect of ADAM10 on exosomes. It was found that knockdown of ADAM10 decreased the eHsp90α content in exosomes, but not the size or the number of exosomes ( Figure 5D-H) . In summary, ADAM10 regulated Hsp90α secretion by affecting its content in exosomes, not by the classical direct sheddase function.
| Western blotting and quantitative proteomic methods determine high levels of plasma Hsp90α from partial false ELSIA-negative patients
Different glycoforms of AFP, AFP-L1 to AFP-L3 have been identified in the serum of HCC patients. 37 In addition, Chiosis's group reported that multiple Hsp90 species existed in cancer cells. 38 All these finding promoted us to test whether secreted Hsp90α was also heterogeneous, as this could contribute to the diagnosis uncertainties of plasma Hsp90α. Prior to validation of above hypothesis,
we determined the absolute concentration of plasma Hsp90α from ELISA-negative patients with cancer. Considering that the antibody in the quantitative ELISA kit recognized only the native conformation of antigen, therefore we first used western blotting with a well characterized polyclonal antibody 39 to detect the denatured plasma Hsp90α from ELISA-negative patients. It was found that, in some F I G U R E 6 Western blotting and quantitative proteomic method determined high levels of plasma Hsp90α from partial false ELISA-negative patients. A, Detection by western blotting of plasma Hsp90α from ELISA-negative lung patients with cancer. r90, recombinant Hsp90α (70 ng/mL). B, PRM quantitation of plasma Hsp90α from false ELISAnegative patients. C, Plasma Hsp90α concentration profiles categorized in false ELISA-negative patients with cancer: PRM vs ELISA. PRM detected always a higher concentration of plasma Hsp90α in these patients with cancer. D, Correlation of plasma Hsp90α concentration using two different representative peptides:
LGIHEDSQNR and KHLEINPDHSIIETLR F I G U R E 7 Development of cell line model that could recapitulate the antigen recognition heterogeneity. A, Correlation analysis between secreted Hsp90α and subclone proliferation from different cell lines. Extracellular Hsp90α was quantified using the ELISA kit. Total protein concentration was determined with BCA assay. B, C, Comparison of invasion ability between subclones with low and high secretion of eHsp90α from H1299 cells (B) and MDA-MB-231 cells (C). Different subclones were seeded on Matrigel-coated transwell inserts in the invasion assay. Representative images and quantification results of invasion assays by H1299 cells (Scale bar, 100 μm) or MDA-MB-231 cells (Scale bar, 100 μm) are shown. **P < .01, ***P < .001. D, Immunoblot detecting the levels of eHsp90α from different subclones. E, Sequential immunoprecipitation steps with indicated antibodies quantitatively depleted Hsp90α from the conditioned medium from corresponding subclones. E7, the antibody in the ELISA kit; ab2928, a well-characterized Hsp90α polyclonal antibody; Total, total Hsp90α in immunoprecipitation assay detected with ab2928 false ELISA-negative patients, western blotting detected higher levels of secreted plasma Hsp90α than the cutoff value ( Figure 6A ).
In earlier studies, a quantitative proteomic method was used to quantify other biomarkers, including 14-3-3 protein, gelsolin, leptin, and prostate specific antigen (PSA). 40, 41 In this approach, a PRM-based targeted proteomic platform was used to detect actual concentrations of plasma Hsp90α, especially in ELISA-negative patients. Two peptides, LGIHEDSQNR and KHLEINPDHSIIETLR, were chosen as the signature peptides, and standard curves were drawn to quantify the concentrations of plasma Hsp90α ( Figure S6A ,B).
Analysis of two representative peptide quantifications revealed that different peptides from same protein showed different absolute concentration measurements in determining the concentration of plasma Hsp90α ( Figure 6B ). However, quantitative results from
LGIHEDSQNR and KHLEINPDHSIIETLR correlated ( Figure 6C ), although the average difference in quantification measurements was F I G U R E 8 Secreted Hsp90α hyperphosphorylated by PKCγ confers its antigen heterogeneity. A, Lysates of different subclones transfected with control (Vector) or HA-tagged Hsp90α-expressing vectors were subjected to immunoprecipitation with an anti-HA antibody (IP: HA antibody). The lysates and immunoprecipitates were resolved by SDS/PAGE and immunoblotted with the respective antibodies. B, The immunoprecipitates were probed with the indicated antibodies against corresponding post-translational modifications of secreted Hsp90α. C, Lysates of subclone 6A5 were subjected to detect PKCγ, ATM, DNA-PKcs, and PKA, by which could phosphorylate eHsp90α. D, In vitro phosphorylation of recombinant Hsp90α by PKCγ (inset) and ELISA quantification of the phosphorylated recombinant Hsp90α. E, Heat map of RNA-seq data, which demonstrates similarity in global gene expression between different subclones, including 6A5, low-secretion subclones 6D6 and 9A6, high-secretion subclones 13B5, and wild type H1299 cell line. F, Quantitation of eHsp90α from subclone 6A5 after knockdown of TGFB1, GLI1, and TNF. The bottom panel means the secreted Hsp90α detected by western blotting with ab2928. These three TFs were predicted by IPA analysis to regulate the downstream gene expression leading to the heterogeneity of eHsp90α. G, Immunohistochemical analysis of PKCγ in 10 ELISA-positive patients and 10 false ELISA-negative patients with lung cancer. Samples were divided into two groups, high and higher group, according to the expression of PKCγ; 10 ELISA-positive patients were from Figure 4F , and false ELISA-negative patients were from Figure 6A . Fisher's exact test was used to test the difference between categorical variables. Scale bar, 100 μm 1.89-fold. We also found that, in false ELISA-negative patients, the mean of plasma Hsp90α quantified by PRM proteomics was significantly higher than that quantified by ELISA (7.09-fold for
LGIHEDSQNR and 13.42-fold for KHLEINPDHSIIETLR; Figure 6D and Table S12 ). The above results showed that plasma Hsp90α from partial response patients with cancer was heterogeneous, could not be detected by the ELISA kit, and affected the diagnosis performance of the ELISA kit.
| Development of a cell subclone model recapitulates the plasma Hsp90α recognition heterogeneity in clinic
Considering that tumor heterogeneity confers a unique identity on individual cancer cells, 42 it was hypothesized that the heterogeneity including not being related to cancer cell proliferation, 36 but to promigration/pro-invasion. 43 We used the BCA assay to quantify protein content and an ELISA kit to detect the secreted Hsp90α from clonally expanded subclones in MCF7, A549, H1299, and MDA-MB-231
clones. There was no significant correlation between the rates of proliferation and secretion of Hsp90α ( Figure 7A ). We also used the Unexpectedly, one subclone from H1299, 6A5, showed a comparable invasion ability with subclones from the high-secretion group ( Figure 7B ). We hypothesized that eHsp90α from 6A5 was not recognized by the antibody in the ELISA kit, and classified erroneously into low-secretion group. Therefore, we used western blotting analysis to detect denatured eHsp90α from different subclones. The results showed that the level of eHsp90α from 6A5 was comparable with that from the high-secretion subclones ( Figure 7D ), which suggested that the partial antigen was not originally recognized by the antibody in the kit during the subclone sorting process. To further confirm this conclusion, consecutive immunoprecipitation (IP) assay was performed to recapitulate the heterogeneous eHsp90α from subclone 6A5. Three IP steps with the mentioned characterized polyclonal antibodies for Hsp90α 44 quantitatively depleted eHsp90α ( Figure 7E ). In contrast, sequential pull-downs with the antibody in the ELISA kit removed only a limited fraction of eHsp90α from subclone 6A5 ( Figure 7E ). All these results proved that subclones expanded from single cell can recapitulate the properties of eHsp90α and reflect the heterogeneity in antigen recognition.
| Hsp90α hyperphosphorylated by PKCγ confers antigen heterogeneity
Having established an in vitro cell model capable of heterogeneous antigen profiling, we next investigated the underlying mechanisms.
It was reported that secreted Hsp90α can be phosphorylated 36 Table S13 ). Next, using IPA analysis, we identified the upstream transcriptional regulators that could most probably explain the heterogeneity of eHsp90α in 6A5, and three transcription factors, including T-cell growth factor beta 1 (TGFB1), GLI1, and tumor necrosis factor (TNF), were chosen for further analysis. To validate the results of the IPA analysis, we knocked down these three TFs in subclone 6A5
and found that the ELISA kit could detect more eHsp90α from subclone 6A5 when TGFB1 was knocked down (Figures 8F and S8B ). In the clinic, we also found that the expression of PKCγ in false ELSIAnegative patients was higher than that in ELISA-positive patients ( Figure 8G ). All these results indicated that TGFB1-PKCγ defines a distinct pool of eHsp90α hyperphosphorylated at threonine residues that can affect the diagnostic performance of plasma Hsp90α in the clinic. to catalyze many cell surface endoproteolytic events, including Notch, E-cadherin, epidermal growth factor (EGF), ErbB2, CX3CL-1, IL-6 receptor, CD44, CD23, and L1. 34 Therefore, it is possible that these cytokines or signaling molecules mediate indirectly the secretion of Hsp90α in the regulation of ADAM10.
| D ISCUSS I ON
Emerging studies have also reported that ADAM10 is required for CD23 or L1 sorting into exosomes. 55, 56 The exact mechanism underlying ADAM10 in mediating the secretion of Hsp90α needs further studies. We also examined the signaling pathways in regulating the secretion of Hsp90α after dysregulating the expression of ADAM10. No consistent conclusions could be drawn from multiple cancer cell lines (data not shown). Furthermore, many other factors, including FKBP52, PKA, PP5, CHIP, Cyp40, 36 HIF1α, 49 and HDAC6, 44 have been reported to be involved in the secretion of Hsp90α. Consequently, the relationships between these factors and ADAM10 also need further investigation.
Western blotting and proteomic methods tend to measure the actual total concentration in a denatured setting. However, the ELISA kit quantifies the target proteins through an epitope exposed in solution. In addition, the interaction between target antigen and antibody in a kit can also be affected by autoantibodies, other bound proteins, or even post-translational modifications (PTM). In our study, it was found that threonine residues in plasma Hsp90α hyperphosphorylated by PKCγ affected the diagnostic capability of the ELISA kit. PKC, known as a family of serine/threonine kinases, contributes to several cancer progressions including tumor migration and invasion. 57 The γ isoform has been shown to be a substrate of Hsp90, and Hsp90α can be phosphorylated by PKCγ. 20 However, the mechanisms underlying PKCγ hyperphosphorylated Hsp90α in those specific population still are not known. The glycoform AFP-L3, 37 but not L1 or L2, is the marker for hepatocellular carcinoma. Wu and coworkers 58 have reported that N-glycan heterogeneity of α1-acid glycoprotein (AGP) and haptoglobin (Hp) will regulate the interactions of plasma proteins. Meanwhile, it has been reported that phosphorylation of Hsp90 can affect its interaction with co-chaperones or client proteins. 59, 60 However, limited by current techniques, the detection of specific sites modified in plasma Hsp90α failed in our study. It is possible that knowledge of the defined spatial position of residues with PTMs and how these PTMs control structure conformation in extracellular Hsp90α is critical for its quantification. All these detailed mechanism studies provide a rational interpretation for its use as a diagnostic biomarker in the clinic, and will ultimately lead to a way to improve the diagnostic performance of the current ELISA kit.
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